


Supplemental Figure for:  
Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma  
Silvia Stacchiotti et al.



**Figure S1.** Progression Free Survival (PFS) comparison between patients naïve from antiangiogenics versus patients treated with another antiangiogenic agent before starting pazopanib. Median PFS in untreated patients was 14.4 months versus 12.2 months in those pretreated with an antiangiogenic drug.